Cargando...
Synergistic combinations of paclitaxel and withaferin A against human non-small cell lung cancer cells
Platinum-taxane combination chemotherapy still represents the standard of care for advanced non-small cell lung cancer (NSCLC) with no targetable driver mutations. However, the efficacy of these drugs has plateaued at 10–14 months primarily due to dose-limiting toxicity, chemoresistance, and metasta...
Guardado en:
| Publicado en: | Oncotarget |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Impact Journals LLC
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7185067/ https://ncbi.nlm.nih.gov/pubmed/32362998 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27519 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|